Brief: Impact Biomedical's Proprietary Equivir Compound To Treat Viral Infection Receives Clean Patentability Report From World Intellectual Property Organization's Isa Division
03/03/2022 15:43
March 3 (Reuters) - DSS Inc DSS.A :
* IMPACT BIOMEDICAL’S PROPRIETARY EQUIVIR COMPOUND TO TREAT
VIRAL
INFECTION RECEIVES CLEAN PATENTABILITY REPORT FROM WORLD
INTELLECTUAL PROPERTY ORGANIZATION’S ISA DIVISION
Source text for Eikon: ID:nGNX5Fcclx
Further company coverage: DSS.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DSS
See all newsBrief: Dss Withdraws S-1 Registration Statement With SEC
Brief: Dss Reports Going Concern Audit Opinion In 2025 10-K Filing
Brief: Dss Inc Actively Evaluating Acquisition Opportunities Within Folding Carton Space
Brief: Dss, Inc. Announces Pricing Of $1.0 Million Underwritten Public Offering
Brief: DSS’s Subsidiary, Impact Biomedical, Announces Strategic Merger